Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $64,000.

  • NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) rose 128.57% to $64,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $212,000, marking a year-over-year increase of 182.67%. This contributed to the annual value of $113,000 for FY2024, which is 130.61% up from last year.
  • NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) amounted to $64,000 in Q3 2025, which was up 42.22% from $45,000 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) registered a high of $64,000 during Q3 2025, and its lowest value of $9,000 during Q1 2023.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) averaged around $29,364, with its median value being $19,000 (2024).
  • Data for NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) shows a peak YoY spiked of 292.31% (in 2024) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Depreciation & Amortization (CF) (Quarterly) stood at $13,000 in 2023, then skyrocketed by 292.31% to $51,000 in 2024, then spiked by 128.57% to $64,000 in 2025.
  • Its last three reported values are $64,000 in Q3 2025, $45,000 for Q2 2025, and $52,000 during Q1 2025.